JP2022527860A5 - - Google Patents

Info

Publication number
JP2022527860A5
JP2022527860A5 JP2021560390A JP2021560390A JP2022527860A5 JP 2022527860 A5 JP2022527860 A5 JP 2022527860A5 JP 2021560390 A JP2021560390 A JP 2021560390A JP 2021560390 A JP2021560390 A JP 2021560390A JP 2022527860 A5 JP2022527860 A5 JP 2022527860A5
Authority
JP
Japan
Prior art keywords
chain
sequence
antigen
chains
binding site
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021560390A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527860A (ja
JP7716623B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/026261 external-priority patent/WO2020206033A1/en
Publication of JP2022527860A publication Critical patent/JP2022527860A/ja
Publication of JP2022527860A5 publication Critical patent/JP2022527860A5/ja
Application granted granted Critical
Publication of JP7716623B2 publication Critical patent/JP7716623B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021560390A 2019-04-02 2020-04-01 排出ポンプ-癌抗原マルチ特異性抗体ならびにそれに関する組成物、試薬、キットおよび方法 Active JP7716623B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962828044P 2019-04-02 2019-04-02
US62/828,044 2019-04-02
US202062967478P 2020-01-29 2020-01-29
US62/967,478 2020-01-29
PCT/US2020/026261 WO2020206033A1 (en) 2019-04-02 2020-04-01 Efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto

Publications (3)

Publication Number Publication Date
JP2022527860A JP2022527860A (ja) 2022-06-06
JP2022527860A5 true JP2022527860A5 (cg-RX-API-DMAC7.html) 2023-03-31
JP7716623B2 JP7716623B2 (ja) 2025-08-01

Family

ID=70465444

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021560390A Active JP7716623B2 (ja) 2019-04-02 2020-04-01 排出ポンプ-癌抗原マルチ特異性抗体ならびにそれに関する組成物、試薬、キットおよび方法

Country Status (9)

Country Link
US (1) US12331121B2 (cg-RX-API-DMAC7.html)
EP (1) EP3946626A1 (cg-RX-API-DMAC7.html)
JP (1) JP7716623B2 (cg-RX-API-DMAC7.html)
CN (1) CN113692413A (cg-RX-API-DMAC7.html)
AU (1) AU2020253449B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021019701A2 (cg-RX-API-DMAC7.html)
CA (1) CA3131895A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021012003A (cg-RX-API-DMAC7.html)
WO (1) WO2020206033A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12692311B2 (en) 2020-01-29 2026-07-28 William Robert Arathoon Living Trust Dated August 29, 2016 Anti-MDR1 antibodies and uses thereof
CN112656941A (zh) * 2021-01-20 2021-04-16 福建医科大学附属协和医院 抗cd47单克隆抗体在制备抗阿霉素耐药的急性淋巴细胞白血病细胞的药物中应用
EP4288050A1 (en) * 2021-02-08 2023-12-13 Takeda Pharmaceutical Company Limited Combination therapy for cancer treatment
KR20240116829A (ko) * 2021-12-13 2024-07-30 윌리엄 로버트 아라툰 리빙 트러스트 데이티드 어거스트 29, 2016 항-abcb1 항체
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies
AU2023315757A1 (en) * 2022-07-28 2025-02-13 Shenzhen Enduring Biotech , Ltd. Peg based anti-cd47/anit-pd-l1 bispecific antibody-drug conjugate
EP4633661A2 (en) * 2022-12-16 2025-10-22 Washington University Compositions and methods of treatment for neuroinflammation-related disorders
CN122580338A (zh) * 2024-01-19 2026-08-14 安进公司 具有两个轻链拷贝的表达载体系统

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
JP2564412B2 (ja) * 1990-03-02 1996-12-18 財団法人癌研究会 薬剤耐性癌に対するキメラ抗体およびその製造
US5948647A (en) * 1990-10-29 1999-09-07 Chiron Corporation Nucleic acids encoding antigen-binding sites specific for cancer antigens
US5849877A (en) 1990-10-29 1998-12-15 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
AU8727291A (en) * 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
TW197439B (cg-RX-API-DMAC7.html) 1991-04-04 1993-01-01 Ueno Pharmaceutics Applic Res Co Ltd
ATE237694T1 (de) 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
WO1993010076A1 (en) 1991-11-22 1993-05-27 The University Of Mississippi Synthesis and optical resolution of the taxol side chain and related compounds
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
AU4242993A (en) 1992-05-21 1993-12-13 Penn State Research Foundation, The Cultured (taxus) tissues as a source of taxol, related taxanes and other novel anti-tumor/anti-viral compounds
US5274137A (en) 1992-06-23 1993-12-28 Nicolaou K C Intermediates for preparation of taxols
US5294637A (en) 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5202448A (en) 1992-08-14 1993-04-13 Napro Biotherapeutics, Inc. Processes of converting taxanes into baccatin III
CA2100808A1 (en) 1992-10-01 1994-04-02 Vittorio Farina Deoxy paclitaxels
FR2696461B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent.
FR2696464B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.
FR2696458B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2696462B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696463B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
EP0673431A1 (en) 1992-12-03 1995-09-27 Genzyme Corporation Gene therapy for cystic fibrosis
US5279949A (en) 1992-12-07 1994-01-18 Board Of Trustees Operating Michigan State University Process for the isolation and purification of taxol and taxanes from Taxus spp
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
US5824701A (en) 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
DE69435223D1 (de) 1993-10-25 2009-09-03 Canji Inc Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
WO1998008833A1 (en) 1996-08-26 1998-03-05 Bristol-Myers Squibb Company Sulfenamide taxane derivatives
AU739028B2 (en) 1996-09-27 2001-10-04 Bristol-Myers Squibb Company Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
WO1998022451A1 (en) 1996-11-19 1998-05-28 Daiichi Pharmaceutical Co., Ltd. Taxol derivatives
US5977386A (en) 1996-12-24 1999-11-02 Bristol-Myers Squibb Company 6-thio-substituted paclitaxels
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
IL133585A0 (en) 1997-06-20 2001-04-30 Baker Norton Pharma Soluble prodrugs of paclitaxel
US7288665B1 (en) 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
JPH1192468A (ja) 1997-09-17 1999-04-06 Yakult Honsha Co Ltd 新規なタキサン誘導体
WO1999018113A1 (fr) 1997-10-08 1999-04-15 Bio Research Corporation Of Yokohama Derives taxoides et leur procede de production
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1865987A2 (en) 2005-04-06 2007-12-19 Cedars-Sinai Medical Center Inhibition of p-glycoprotein by treatment with a class of modulators and the uic2 monoclonal antibody
AU2011252851B2 (en) * 2010-05-14 2016-10-06 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to CD47
TWI888366B (zh) * 2013-07-16 2025-07-01 美商建南德克公司 利用pd-1軸結合拮抗劑及tigit抑制劑治療癌症之方法
CN110658340B (zh) * 2015-01-08 2023-10-31 苏州康宁杰瑞生物科技有限公司 具有共同轻链的双特异性抗体或抗体混合物

Similar Documents

Publication Publication Date Title
JP2021527431A5 (cg-RX-API-DMAC7.html)
JP2022101693A5 (cg-RX-API-DMAC7.html)
JP2024522360A5 (cg-RX-API-DMAC7.html)
JP2023002615A5 (cg-RX-API-DMAC7.html)
JP2017535257A5 (cg-RX-API-DMAC7.html)
JP2020516240A5 (cg-RX-API-DMAC7.html)
JP2022542165A5 (cg-RX-API-DMAC7.html)
JP2020502271A5 (cg-RX-API-DMAC7.html)
JP2026041756A5 (cg-RX-API-DMAC7.html)
JP2008532949A5 (cg-RX-API-DMAC7.html)
JP2023549537A5 (cg-RX-API-DMAC7.html)
RU2015141428A (ru) Антитела, связывающие il-4 и/или il-13, и их применение
JP2025183307A5 (cg-RX-API-DMAC7.html)
JP2022533538A5 (cg-RX-API-DMAC7.html)
JP2023531185A5 (cg-RX-API-DMAC7.html)
JP2020501598A5 (cg-RX-API-DMAC7.html)
JP2023545183A5 (cg-RX-API-DMAC7.html)
JP2020500834A5 (cg-RX-API-DMAC7.html)
JP2023506750A5 (cg-RX-API-DMAC7.html)
JP2012532851A5 (cg-RX-API-DMAC7.html)
JP2017521054A5 (cg-RX-API-DMAC7.html)
JP2018528759A5 (cg-RX-API-DMAC7.html)
RU2017114968A (ru) Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171)
JP2023512196A5 (cg-RX-API-DMAC7.html)
JP2023528416A5 (cg-RX-API-DMAC7.html)